FOGHORN THERAPEUTICS I

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

07 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference

25 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides an Update on FHD-609

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting

10 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

06 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

09 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference

01 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023

09 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference

22 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit

20 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference

27 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

01 Sep 2022 16:05:00 By Nasdaq GlobeNewswire